Global Retinal Drugs Market 2024-2028

Global Retinal Drugs Market 2024-2028

Global Retinal Drugs Market 2024-2028

The retinal drugs market is forecasted to grow by USD 8.40 bn during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the retinal drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in prevalence of retinal diseases, emergence of advanced diagnostic tools, and patient assistance programs.

Technavio's retinal drugs market is segmented as below:

• By Distribution Channel
• Hospital pharmacy
• Retail pharmacy
• Online pharmacy
• By Indication
• Macular degeneration
• Diabetic eye disease
• Others
• By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the development of innovative therapies as one of the prime reasons driving the retinal drugs market growth during the next few years. Also, rise in demand for sustained-release ocular formulations and advances in diagnostic techniques will lead to sizable demand in the market.

The report on the retinal drugs market covers the following areas:

• Retinal drugs market sizing
• Retinal drugs market forecast
• Retinal drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading retinal drugs market vendors that include AbbVie Inc., Alcon Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc., Kubota Corp., MeiraGTx Holdings Plc., Novartis AG, Ocular Therapeutix Inc, Oxurion N, Pfizer Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc, Sanofi SA, Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Visufarma. Also, the retinal drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.